0001213900-26-048288
SEC filingProfusa, Inc. is a clinical-stage digital health company developing injectable biosensors for real-time tissue oxygen and glucose monitoring, with CE-marked Lumee Oxygen in Europe and FDA approvals pending. This S-1 registers resale of up to 179M shares by selling stockholders under ELOC and note conversions, enabling up to $100M in potential funding.
Profusa operates in the high-growth continuous monitoring medtech space, leveraging a proprietary hydrogel sensor platform injectable via hypodermic needle that integrates with tissue to avoid foreign body response, enabling months-long functionality versus competitors' short-term needle-based CGMs (Dexcom, Abbott) requiring weekly replacement. Lumee Oxygen, CE-marked since 2020, targets critical limb ischemia wound care—a $200B U.S. annual cost market affecting 5M patients—measuring tissue oxygenation post-revascularization where 50% of procedures fail to heal wounds due to microvascular issues. Lumee Glucose shows 11.7% MARD in 54-subject trials with 9-month potential, positioning for broader Type 2/pre-diabetes adoption beyond Type 1. No U.S. approvals yet; EU Oxygen launch targeted early 2026 pending MDR migration, U.S. FDA submissions planned late 2026.
Financially, Profusa burned $16.2M operating cash in 2025 on $35.8M net loss (vs. $9.2M prior year), with $1.8M cash post-ELOC draws and PIPE. Going concern warning persists despite $100M ELOC capacity ($10.3M drawn) and $13.9M Ascent Notes. This S-1 registers resale of 179M shares (150M ELOC Purchase Shares at 97% VWAP floor $0.14 post-1:75 RSS, 20M Note conversions, 3.3M inducement warrants, 5.3M Sponsor conversions), representing ~97% dilution at current 4.4M shares outstanding. Proceeds solely to company from future ELOC draws ($89.7M remaining capacity) for working capital; no dilution to existing holders from resales.
Key risks center on regulatory delays (no U.S. sales without FDA), Nasdaq delisting (bid price/MVLS failures post-RSS; hearing April 2026), execution (commercial traction unproven), and funding dependence (ELOC floor risks access if shares < $0.14). Material weaknesses in controls (segregation of duties, complex instruments) persist. Management led by CEO Ben Hwang (ex-Life Tech exec) and CSO Bill McMillan (co-inventor) brings deep biosensor expertise; board includes finance vets from NuVasive, Interpace.
Investor opportunity lies in platform's moat (DARPA/NIH-funded, 57 patents to 2040) addressing $3.5B+ TAM in oxygen/CGM, but high execution risk given pre-revenue status, Nasdaq woes, and dilution overhang. ELOC provides flexible capital absent traditional VC/IPO, but resale pressure could suppress shares ($0.60 last trade April 23, 2026).